Charles Schwab’s Pulse Biosciences PLSE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.21M Buy
151,991
+4,223
+3% +$99.7K ﹤0.01% 2546
2026
Q1
$3.19M Sell
147,768
-4,652
-3% -$85.9K ﹤0.01% 2584
2025
Q4
$2.09M Sell
152,420
-238
-0.2% -$3.71K ﹤0.01% 2747
2025
Q3
$2.7M Sell
152,658
-19,749
-11% -$312K ﹤0.01% 2678
2025
Q2
$2.6M Buy
172,407
+22,768
+15% +$378K ﹤0.01% 2592
2025
Q1
$2.41M Buy
149,639
+433
+0.3% +$8.07K ﹤0.01% 2554
2024
Q4
$2.6M Buy
149,206
+1,092
+0.7% +$19.3K ﹤0.01% 2600
2024
Q3
$2.6M Buy
148,114
+97,565
+193% +$1.66M ﹤0.01% 2627
2024
Q2
$566K Buy
50,549
+6,854
+16% +$64.6K ﹤0.01% 3144
2024
Q1
$381K Hold
43,695
﹤0.01% 3122
2023
Q4
$535K Hold
43,695
﹤0.01% 3056
2023
Q3
$176K Hold
43,695
﹤0.01% 3307
2023
Q2
$314K Buy
+43,695
New +$279K ﹤0.01% 3216
2022
Q2
Sell
-30,780
Closed -$150K 3621
2022
Q1
$150K Sell
30,780
-5,314
-15% -$43.5K ﹤0.01% 3357
2021
Q4
$535K Buy
36,094
+1,540
+4% +$30.7K ﹤0.01% 3122
2021
Q3
$747K Sell
34,554
-258
-0.7% -$5.55K ﹤0.01% 2991
2021
Q2
$571K Sell
34,812
-814
-2% -$15.5K ﹤0.01% 3121
2021
Q1
$844K Buy
35,626
+2,018
+6% +$60.3K ﹤0.01% 2908
2020
Q4
$802K Buy
33,608
+2,406
+8% +$38.3K ﹤0.01% 2837
2020
Q3
$368K Sell
31,202
-1,732
-5% -$18.6K ﹤0.01% 2968
2020
Q2
$345K Buy
32,934
+5,941
+22% +$53.5K ﹤0.01% 2980
2020
Q1
$194K Hold
26,993
﹤0.01% 3017
2019
Q4
$362K Hold
26,993
﹤0.01% 2931
2019
Q3
$417K Hold
26,993
﹤0.01% 2874
2019
Q2
$357K Buy
26,993
+1,853
+7% +$25.3K ﹤0.01% 2961
2019
Q1
$443K Buy
25,140
+2,240
+10% +$35.1K ﹤0.01% 2800
2018
Q4
$263K Buy
22,900
+3,000
+15% +$36.3K ﹤0.01% 2973
2018
Q3
$283K Buy
19,900
+4,500
+29% +$63.9K ﹤0.01% 3017
2018
Q2
$234K Buy
15,400
+100
+0.7% +$1.69K ﹤0.01% 3043
2018
Q1
$208K Hold
15,300
﹤0.01% 2981
2017
Q4
$362K Hold
15,300
﹤0.01% 2818
2017
Q3
$285K Hold
15,300
﹤0.01% 2892
2017
Q2
$529K Buy
+15,300
New +$421K ﹤0.01% 2672

Other funds holding PLSE

Charles Schwab's PLSE Position: Q2 2026 in Review

Charles Schwab increased its Pulse Biosciences (PLSE) stake by 2.9% in Q2 2026, buying an estimated $99.7K and bringing the position to 151,991 shares worth $4.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2546.

Charles Schwab first reported a position in PLSE in Q2 2017 and has held it in 33 quarters since. 106 funds tracked by Wall St. Rank hold PLSE as of Q2 2026.

  • Charles Schwab held 151,991 shares of Pulse Biosciences worth $4.21M as of Q2 2026.
  • Charles Schwab bought 4,223 Pulse Biosciences shares in Q2 2026, an estimated $99.7K.
  • Pulse Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2546 holding.
  • Charles Schwab first reported a position in Pulse Biosciences in Q2 2017 and has held it in 33 quarters since.
  • 106 funds tracked by Wall St. Rank held Pulse Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.